A Long-Term International, Extension of Study GNC-003, with GNbAC1 in Patients with Relapsing Remitting Multiple Sclerosis

Trial Profile

A Long-Term International, Extension of Study GNC-003, with GNbAC1 in Patients with Relapsing Remitting Multiple Sclerosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs GNbAC1 (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms ANGEL-MS
  • Sponsors GeNeuro
  • Most Recent Events

    • 21 Dec 2016 New trial record
    • 07 Dec 2016 According to a Servier media release, this trial will be conducted in parallel with any Phase III studies that might be launched based on the results of the CHANGE-MS study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top